Sandberg M.; Schellmann D.; Brunhofer G.; Erker T.; Busygin I.; Leino R.; Vuorela P. and Fallarero A. Pros and cons of using resazurin staining for quantification of viable Staphylococcus aureus biofilms in a screening assay. (2009). Journal of Microbiological Methods. 78(1):104-106 .

Lehtiö, L., Ann-Sofie Jemth, A.-S., Collins, R., Loseva, O., Johansson, A., Markova, N., Martin Hammarström, M., Flores, A., Holmberg-Schiavone, L., Weigelt, J., Helleday, T., Schüler, H. & Karlberg, T. (2009) Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52:3108-11.

Collins, R., Karlberg, T., Lehtiö, L., Schütz, P., van den Berg, S., Dahlgren, L.-G., Hammarström, M., Weigelt, J. & Schüler, H. (2009) The DExD/H-box RNA helicase DDX19 is regulated by an alpha -helical switch. J. Biol. Chem. 284:10296-300.

Miroshnyk I, Mirza S, Sandler N, Pharmaceutical co-crystals-an opportunity for drug product enhancement, Expert Opinion on Drug Delivery, 2009, 6(4), 333-341

Galkin A., Jokela J., Wahlsten M., Tammela P., Sivonen K. Vuorela P. (2009). Discovering protein kinase C active plants growing in Finland utilizing automated bioassay combined to LC/MS. Natural Product Communications4:139-142.

Galkin A., Fallarero A., Vuorela P. (2009): Coumarins permeability in Caco-2 cell model. Journal of Pharmacy and Pharmacology 61:177-184.

Fallarero A., Ainasoja M., Sandberg M., Teeri T.H., Pia M. Vuorela P.M. (2009): GT1-7 Cell-Based cytoxicity screening assay on 96-well microplates as a platform for the safety assessment of genetically modified Gerbera hybrida extracts. Drug and Chemical Toxicology, 32:120-127.

Sabiruddin M., Miroshnyk I., Heinämäki J., Antikainen O., Rantanen J., Vuorela P., Vuorela H., Yliruusi J. (2009): Crystal morphology engineering of pharmaceutical solids: tabletting performance enhancement. AAPS PharmSciTech 10:113-9.